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Telomerase canonical activity at telomeres prevents telomere shortening, allowing chro-
mosome stability and cellular proliferation. To perform this task, the catalytic subunit
(telomerase reverse transcriptase, TERT) of the enzyme works as a reverse transcriptase
together with the telomerase RNA component (TERC), adding telomeric repeats to DNA
molecule ends. Growing evidence indicates that, besides the telomeric-DNA synthesis
activity, TERT has additional functions in tumor development and is involved in many differ-
ent biological processes, among which cellular proliferation, gene expression regulation,
and mitochondrial functionality. TERT has been shown to act independently ofTERC in the
Wnt-β-catenin signaling pathway, regulating the expression of Wnt target genes, which
play a role in development and tumorigenesis. Moreover, TERT RNA-dependent RNA poly-
merase activity has been found, leading to the genesis of double-stranded RNAs that
act as precursor of silencing RNAs. In mitochondria, a TERT TERC-independent reverse
transcriptase activity has been described that could play a role in the protection of mito-
chondrial integrity. In this review, we will discuss some of the extra-telomeric functions of
telomerase.
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INTRODUCTION
Telomerase has been discovered as the enzyme that maintains
telomeric DNA, that is the DNA forming the physical ends of
the eukaryotic chromosomes, the telomeres (Greider and Black-
burn, 1985). In most eukaryotes, telomeric DNA is composed of
tandem repetitions of short DNA sequences, in humans and in all
vertebrates the TTAGGG hexanucleotide. In all organisms, telom-
eric DNA is bound to speciﬁc proteins (Blackburn and Gall, 1978;
Moyzis et al., 1988; Palm and de Lange, 2008). Due to the catalytic
properties of conventional DNA polymerases, telomeres require
dedicated mechanisms for their replication and telomerase is the
main telomere maintenance player.
Telomerase is an RNA–protein complex with reverse transcrip-
tase activity, which contains both the protein catalytic subunit
(telomerase reverse transcriptase, TERT) and the RNA template
(telomerase RNA component, TERC) for the synthesis of the
telomeric DNA (Collins, 2006). At each cell cycle, it binds to
and elongates telomeres. When telomerase is low or absent, as
in normal somatic cells, telomeres shorten at each cell division.
Below a threshold length, telomeres activate DNA double strand
break checkpoints, leading to cellular senescence, a permanent
replicative arrest, or to cell death trough apoptosis (van Steensel
et al., 1998; Masutomi et al., 2003; Rodier and Campisi, 2011).
Telomere shortening can have a dramatic impact on stem cell pro-
liferation, impairing their ability to regenerate tissues (Flores and
Blasco, 2010). On the other hand, when telomerase is expressed
constitutively, as in cancer cells, it allows telomere maintenance
and an unlimited cellular proliferation (Shay and Bacchetti, 1997;
Harley, 2008).
Because of its telomeric function, telomerase plays critical
roles in cancer, aging, and degenerative diseases; nevertheless,
accumulating evidence indicates that telomerase is also involved in
these processes through functions independent of telomeric DNA
synthesis. The purpose of this review is to discuss some of the
recent discoveries about these telomere-independent functions.
TERT, CANCER, AND APOPTOSIS
Cloning of the TERT gene allowed demonstrating the role of
telomere shortening in cellular senescence, as well as the role
of telomerase in cellular immortalization (Bodnar et al., 1998).
In fact, in several human somatic cells, exogenous TERT expres-
sion was found to be sufﬁcient to reconstitute telomerase activity,
stabilize telomere length, and consent an unlimited replica-
tive potential. However, the study of genetically modiﬁed cells
or mice in which TERT had been exogenously expressed also
revealed novel telomerase functions in tumorigenesis (Gonzalez-
Suarez et al., 2001; Artandi et al., 2002; Stewart et al., 2002;
Canela et al., 2004).
Since many reviews have dealt with telomerase telomere-
independent activities possibly involved in tumorigenesis (Mon-
dello and Scovassi, 2004; Belgiovine et al., 2008; Bollmann, 2008;
Cong and Shay, 2008; Majerska et al., 2011; Martinez and Blasco,
2011), here below we will only brieﬂy remind a few relevant points
concerning this topic.
1. TERT expression can promote cell growth and proliferation
independently of telomere elongation by inducing or inhibit-
ing the expression of pro-proliferative and anti-proliferative
genes, respectively. By that, it enables the cells to proliferate
in the absence of mitogenic stimuli, a hallmark of cancer cells
(Stampfer et al., 2001; Lindvall et al., 2003; Smith et al., 2003;
Geserick et al., 2006).
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2. TERT can increase resistance to chemotherapeutic agents and
pro-apoptotic stimuli, possibly blocking the mitochondrial
death pathway (Dudognon et al., 2004; Del Bufalo et al., 2005;
Mondello et al., 2006; Lee et al., 2008).
3. TERT can modulate chromatin structure and response to DNA
damage (Sharma et al., 2003; Masutomi et al., 2005; Gu et al.,
2008).
4. TERT can increase cancer cell ﬁtness improving mitochon-
drial activity and resistance to apoptosis (see Section “TERC-
independent Reverse Transcriptase Activity” and references
therein).
5. TERT can stabilize telomeres in a telomere-capping dependent
manner increasing cell’s lifespan without telomere lengthening
(Zhu et al., 1999; Kim et al., 2003; Mukherjee et al., 2011).
Recently, Okamoto et al. (2011) suggested TERT involvement
in carcinogenesis through cancer stem cell (CSC) maintenance.
According to these authors, TERT forms a complex with a tran-
scriptional regulator, BRG1 (see below), and a GTP-binding
protein overexpressed in stem cells and cancers, nucleostemin
(Tsai and McKay, 2002), which is essential to drive transcriptional
programs relevant for the maintenance of the CSC phenotype
(Okamoto et al., 2011). This TERT function is independent of
its role at telomeres and could contribute to tumorigenesis by
increasing the proportion of CSCs within a tumor.
TERT AND GENE EXPRESSION REGULATION
Telomere shortening due to insufﬁcient telomerase activity
undoubtedly threaten organisms’ health, as shown in experimen-
tal mouse models and in human syndromes, such as for example
Dyskeratosis congenita (Dokal, 2011). In this syndrome, muta-
tions in genes coding for TERT, TERC, or dyskerin, another
subunit of human telomerase (Cohen et al., 2007), lead to telom-
ere shortening and organ failure, probably because of a reduction
in stem cell compartments (Flores and Blasco, 2010). Neverthe-
less, evidence has been reported that TERT can also operate in cell
physiology through additional mechanisms.
Studies on mice overexpressing TERT in the skin suggested
that TERT is involved in stem cell mobilization (Flores et al., 2005;
Sarin et al., 2005). These works demonstrated that TERT over-
expression promotes activation of quiescent bulge stem cells and
hair growth, independently of telomere elongation, indicating that
TERT can activate pathways involved in stem cell renewal. To this
regard, Choi et al. (2008) showed that conditionally TERT expres-
sion in mouse skin induces a gene expression proﬁle resembling
the transcriptional program regulated byWnt, awell knownplayer
in stem cell maintenance and proliferation, as well as in cellular
transformation (Van Mater et al., 2003; Reya and Clevers, 2005;
Wege et al., 2011). Park et al. (2009) undisclosed the connection
between TERT, stem cell proliferation and the Wnt pathway show-
ing that TERT directly modulates the Wnt pathway by acting as a
transcription factor in β-catenin complexes. In fact, TERT inter-
acts with BRG1, a chromatin remodeler binding to β-catenin and
involved in the Wnt signaling (Barker et al., 2001), and promotes
the expression of several β-catenin target genes in a BRG1-
dependent way. Moreover, TERT was found not only to bind to
promoters responsive to Wnt signaling, but also to interact with
the same promoter elements recognized by BRG1 and β-catenin
(Park et al., 2009).
Recently, the telomere-independent TERT role in Wnt sig-
naling was shown to be involved in kidney pathologies, such as
collapsing glomerulopathies (Shkreli et al., 2012). Both idiopathic
and HIV-associated collapsing glomerulopathies are characterized
by proliferation of glomerular differentiated epithelial cells, the
podocytes. Podocytes are an essential part of the glomerular ﬁltra-
tion membrane and their proliferation compromises the kidney
ﬁltration barrier, leading to severe organ damage (Barisoni et al.,
2000). Using a transgenic mouse model conditionally expressing
TERT, Shkreli et al. (2012) showed that induction of the transgene
led to TERT expression in several tissues and to the development
of kidney abnormalities resembling those observed in human col-
lapsing glomerulopathies, including podocyte proliferation. TERT
effects on glomerulus were independent of its catalytic activity,
but linked to its Wnt signaling induction, with increased expres-
sion and nuclear localization of β-catenin. More importantly,
TERT upregulation and β-catenin stabilization were also found in
human and mouse HIV-associated glomerulopathies, indicating
that TERT-mediated Wnt activation can be required for podocyte
proliferation in these diseases. The observation that TERT silenc-
ing and Wnt pathway inactivation in transgenic mice can revert
the podocyte phenotype suggests TERT and Wnt as new targets to
ﬁght collapsing glomerulopathies.
Bernardes de Jesus et al. (2012) found indications forWnt path-
way activation in several organs, including kidney, of 2-year-old
mice treated with an adeno-associated virus (AAV) expressing
mouse TERT. However, in contrast with Shkreli et al.’s (2012)
results, these authors did not report any signs of kidney failure
in these mice, despite increased expression of active β-catenin and
of its target gene cyclin D1 in this organ. In these mice, TERT had
an anti-aging effect strictly dependent on its catalytic telomere
lengthening activity, leading to an extension of mouse life span,
with beneﬁcial effects on health and ﬁtness (Bernardes de Jesus
et al., 2012). A few factors could explain the differences in the two
groups’ﬁnding, including the lack of a completeWntpathway acti-
vation in the mouse studied by Bernardes de Jesus et al. (2012), the
different mouse age at the time of telomerase expression induc-
tion (3 weeks vs. 2 years), possible difference in TERT levels,
or the different mouse strains used for the experiments (FVB/N
strain vs. C57BL6). However, Shkreli et al.’s (2012) observation of
TERT upregulation in human HIV-associated nephropathy, in the
absence of any experimental manipulation, suggests that TERT
overexpression could be a threat for the organism and further
experiments should be performed to ensure a safe use of TERT
exogenous expression for medical purposes.
Recent reports have shown that the relationship between TERT
andWnt pathway activation is in fact bidirectional, both in embry-
onic stem (ES) cells and cancer (Hoffmeyer et al., 2012; Zhang
et al., 2012). Hoffmeyer et al. (2012) found that β-catenin deﬁcient
mice ES cells had shorter telomeres and lower telomerase activity
compared with wild type mice, while longer telomeres and higher
telomerase levels were detected in ES cells expressing an activated
β-catenin. A similar effect on telomere length and telomerase activ-
ity has been shown by inducing or repressing β-catenin expression
in human cancer cell lines (Zhang et al., 2012). It seems that
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β-catenin regulates TERT expression in ES cells through the bind-
ing to the pluripotent transcription factor Klf4, while in human
cancer cells, TERT appears as a direct target of β-catenin/TCF4-
mediated transcription. Thus, activation of the Wnt pathway
during transformation could also participate in some carcinogen-
esis processes through telomerase activity induction and telomere
stabilization.
Although the exogenous TERT expression experiments clearly
indicate telomerase functions independent of its telomere length-
ening activity, comparison of TERC−/− mice with TERT−/−
animals did not show any differences in their phenotypes that
could imply TERT extra-telomeric activities (Vidal-Cardenas and
Greider, 2010; Strong et al., 2011). Even if it is not possible to
exclude that overexpression experiments lead to phenotypes not
related to the real function of the gene under investigation, it is
also conceivable that animals with TERT ablation since the initial
phases of embryogenesis could develop pathways compensating
for TERT inactivation.
TERC-INDEPENDENT TERT CATALYTIC ACTIVITIES
Historically, TERT has been described as an RNA-dependent
DNA polymerase in association with TERC, whose catalytic
activity is carried out at telomeres (Greider and Blackburn,
1985). More recently, a novel TERT function has been found in
post-transcriptional gene silencing as an RNA-dependent RNA
polymerase (RdRP) paired to a mitochondrial non-coding RNA
(Maida et al., 2009); TERT is closely related to viral RdRPs and,
currently, it is the only RdRP identiﬁed in mammals (Maida and
Masutomi, 2011). Moreover, in mitochondria, TERT practices a
TERC-independent reverse transcriptase function that uses mt-
tRNAs as template (Sharma et al., 2012). Finally, the eclectic nature
of TERT catalytic subunit was conﬁrmed by Lue et al. (2005),
who demonstrated that, in particular metal ion concentration,
TERT can work as terminal transferase in a template- and RNA-
independent way (Lue et al., 2005). Mutations in TERT catalytic
domain impair all these enzymatic activities, despite their remark-
able differences in template usage and ﬁnal products, and hence
may affect different physiological processes simultaneously.
TERC-INDEPENDENT RNA-DEPENDENT RNA POLYMERASE ACTIVITY
Isolation of TERT–RNA complexes from HeLa cells overexpress-
ing hTERT demonstrated the existence of at least two equivalent
RNA partners, TERC and mitochondrial RNA processing endori-
bonuclease (RMRP; Maida et al., 2009), a non-coding RNA whose
mutations cause the inherited pleiotropic syndrome Cartilage–
hair hypoplasia (Ridanpaa et al., 2001). TERT–RMRP complex
exhibited RdRP activity and led to production of double-stranded
RMRPRNAmolecules, subsequently processed into 22-nucleotide
siRNAs by RNA-induced silencing complex (RISC). These siRNAs
suppressed RMRP expression, implying TERT role in controlling
gene expression through RNA interference (Maida et al., 2009).
Interestingly, mutations in TERT catalytic domain impaired both
the DNA and RNA polymerase activity.
TERT RdRP has been recently found to have a role in TERT
control of cellular proliferation (Smith et al., 2003; Mukherjee
et al., 2011). In human mammary epithelial cells (HMECs), TERT
transduction enhanced cellular proliferation, both increasing cell
division and reducing apoptosis (Mukherjee et al., 2011). This
effect on cellular proliferation was associated with alterations
in cell cycle regulator proteins, such as cyclin D1 and A2, E2F
and pRB, required telomerase catalytic activity, but was inde-
pendent of TERT activation of Wnt signaling (Mukherjee et al.,
2011). In fact, no transcription induction of Wnt-responsive
genes, targets of TERT (Choi et al., 2008), was observed in TERT-
transduced HMECs. Interestingly, Mukherjee et al. (2011) linked
TERTenhancement of cellular proliferation to a decrease inRMPR
levels. Exogenous TERT expression led to a remarkable reduction
of RMRP levels in HMECs, as a result of a DICER-dependent
processing of double-stranded RMRP molecules synthesized by
RMRP–TERT complex itself. Notably, RMRP shRNA knockdown
gave results comparable to TERT exogenous expression, both in
lowering RMRP levels and improving cellular proliferation. On
the other hand, RMRP knockdown in TERT expressing cells trig-
gered only a minor additional decrease in RMRP levels and a slight
increase in proliferation rate. These data suggest a novel role of
TERT as modulator of cellular proliferation mediated by small
interfering RNAs derived from RNA-dependent DNA polymerase
activity of TERT (Mukherjee et al., 2011).
TERC-INDEPENDENT REVERSE TRANSCRIPTASE ACTIVITY
As mentioned in the second paragraph, TERT is a dually local-
ized protein. It is mainly present in the nucleus, but about
10–20% of cellular TERT localizes in mitochondria (mt), both in
telomerase-expressing normal cells and in cancer cells. TERT has
an N-terminal mitochondrial targeting signal (Santos et al., 2004;
Sharma et al., 2012) and is imported into the organelle, proba-
bly through the binding to a complex containing translocases of
the outer and inner membranes. TERT also binds to several mt-
DNA regions (Haendeler et al., 2009; Sharma et al., 2012). Under
oxidative stress, TERT is reversibly excluded from the nucleus
(Haendeler et al., 2003,2004; Santos et al., 2004,2006) and localizes
in mitochondria (Ahmed et al., 2008). Several reports have shown
that mt-TERT improves mitochondrial function and stress resis-
tance, independently of its telomeric function. This non-telomeric
TERT activity could contribute to tumorigenesis by increasing
tumor cell survival (Ahmed et al., 2008; Haendeler et al., 2009;
Indran et al., 2011; for reviews on telomerase and mitochondria
see Saretzki, 2009; Gordon and Santos, 2010; Indran et al., 2010).
Telomerase reverse transcriptase catalytic activity seems to be
required for TERT mitochondrial effects (Santos et al., 2006).
However, recent evidence indicates that TERC is not present in
mitochondria, suggesting that TERT reverse transcriptase activ-
ity is independent of TERC (Sharma et al., 2012). In support to
this hypothesis, Sharma et al. (2012) showed that wild type TERT
performed its mitochondrial functions even when expressed in
humanVA13 cells, which use the alternative lengthening of telom-
eres (ALT) mechanism and does not contain TERC. Moreover,
in the same cells, a dominant negative form of the enzyme was
inactive.
Given that in mitochondria TERT binds to several mt-tRNAs
and many reverse transcriptases use cellular tRNAs to perform
their synthesis (Herschhorn and Hizi, 2010), mt-TERT could
use tRNAs rather than TERC for cDNA synthesis. To test this
hypothesis, Sharma et al. (2012) ﬁrst translated TERT in rabbit
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reticulocyte lysates (RRLs) in the presence of TERC and demon-
strated that TERT was able to synthesize telomeric repeats in a
TRAP based assay. Subsequently, they added total cellular RNAs
from TERC positive HeLa cells or TERC negative VA13 cells to the
TERT–RRL reactionmixture, aswell as randomhexamers to prime
the reactions. Analysis for the presence of cDNAs was then per-
formed throughPCRwith primers for differentmt-tRNAgenes. In
these in vitro reactions, TERT could clearly perform cDNA synthe-
sis in the absence of TERC.PreincubationwithTERCabolished the
synthesis of non-telomeric cDNAs, while incubation with RNAs
from TERC-positive HeLa cells reduced the reverse transcription
of mt-tRNAs, suggesting that TERCcompeteswith the otherRNAs
for TERT binding. In the absence of TERT, no products were
observed. To conﬁrm these data, Sharma et al. (2012) performed
an in vitro reverse transcriptase reaction using in vitro transcribed
mt-tRNAcys as template together with wtTERT or a dominant-
negative mutant form of the enzyme and found the cDNA corre-
sponding to the template in the ﬁrst case, but not in the second
one. Thus, this work strongly indicates that mt-TERT can work as
a TERC-independent reverse transcriptase that uses mt-tRNAs as
template.
So far, the function of this novel TERT activity is unknown.
However, Sharma et al. (2012) suggested its role in mt-DNA repli-
cation and/or repair. Since a reverse transcriptase activity could
be involved in the priming of the light mt-chain origin (Kaguni,
2004), TERT might have a part in this DNA replication step.
Moreover, TERT’s function in mt-DNA replication might par-
tially explain its ability to counteract mt-DNA loss after ethidium
bromide exposure in telomerase deﬁcient mice (Haendeler et al.,
2009). Very little is known about DNA repair in mitochondria (Liu
and Demple, 2010). In yeast, evidence has been reported that RNA
could be used to repair DNA double strand breaks and then con-
verted into DNA by a reverse transcriptase activity (Storici et al.,
2007). It is possible that TERT participate in this process also in
mammalian cells.
In addition toTERTplaying a protective role inmitochondria, a
recent report demonstrated the inﬂuence of telomere length on the
control of mitochondrial ﬁtness (Sahin et al., 2011). This report
showed that telomere dysfunction in TERT and TERC late gen-
eration knockout mice led to a p53-mediated repression of the
master regulators of mitochondrial physiology and metabolism
peroxisome proliferator-activated receptor gamma, coactivator-1
alpha and beta (PGC-1α and PGC-1β), and to a repression of the
downstream pathway. This resulted in altered mitochondrial bio-
genesis and function, decreased gluconeogenesis, cardiomyopathy,
and increased reactive oxygen species. Restoring TERT or PGC-1α
expression in the TERT knockout mice, or deleting TP53 in the
germline, reverted the phenotype.
FIGURE 1 | Schematic representation of multipleTERT functions. In the
nucleus, TERT can elongate telomeres binding to TERC; binding to BRG1, it
can work as a coactivator of the Wnt pathway and regulate gene expression;
ﬁnally, silencing experiments in somatic cells showed that TERT is involved in
chromatin organization and DNA-damage response. In mitochondria, TERT
plays a role in stress response, apoptosis, and in the maintenance of
mitochondrial ﬁtness; moreover, it can interact with RNAs other thanTERC
acquiring an additional RNA transcriptase activity or an RNA-dependent RNA
polymerase activity. This last activity seems to lead the production of siRNAs
that are involved in post-transcriptional gene expression regulation.
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CONCLUSION AND FUTURE PERSPECTIVES
A large body of evidence indicates that the telomerase complex,
and in particular its TERT subunit, plays several functions beyond
the maintenance of telomere length and chromosome stability
(Figure 1). These functions can impact normal cell physiology but
also cancer cells, giving them a selective advantage. As far as cancer
cells are concerned, the discovery of pathways in which telomerase
can intervene and promote tumorigenesis beyond telomeres could
highlight new possible targets for tumor therapy. Little is known
on mitochondrial TERT in normal somatic cells and on its new
role as mitochondrial RNA-dependent DNA polymerase. Further
investigation of these topics might help clarify TERT role on aging,
in which dysfunctional mitochondria seem to play a relevant role.
Particularly important will be to gain the tools, so far limited,
to study TERT functions in cellular physiological conditions and,
especially, in normal somatic cells, in which the low abundance of
the protein has limited its analysis.
ACKNOWLEDGMENTS
Work in Chiara Mondello’s laboratory is supported by Fondazione
Cariplo (grant no. 2011-0370). We thank Dr. Aya Biran for help in
editing the English style.
REFERENCES
Ahmed, S., Passos, J. F., Birket, M.
J., Beckmann, T., Brings, S., Peters,
H., et al. (2008). Telomerase does
not counteract telomere shortening
but protects mitochondrial function
under oxidative stress. J. Cell Sci. 121,
1046–1053.
Artandi, S. E., Alson, S., Tietze, M. K.,
Sharpless, N. E., Ye, S., Greenberg, R.
A., et al. (2002). Constitutive telom-
erase expression promotes mammary
carcinomas in aging mice. Proc. Natl.
Acad. Sci. U.S.A. 99, 8191–8196.
Barisoni, L., Mokrzycki, M., Sablay,
L., Nagata, M., Yamase, H., and
Mundel, P. (2000). Podocyte cell cycle
regulation and proliferation in col-
lapsing glomerulopathies. Kidney Int.
58, 137–143.
Barker, N., Hurlstone, A., Musisi,
H., Miles, A., Bienz, M., and
Clevers, H. (2001). The chromatin
remodelling factor Brg-1 interacts
with beta-catenin to promote tar-
get gene activation. EMBO J. 20,
4935–4943.
Belgiovine, C., Chiodi, I., and Mon-
dello, C. (2008). Telomerase: cellu-
lar immortalization and neoplastic
transformation. Multiple functions
of a multifaceted complex. Cyto-
genet. Genome Res. 122, 255–262.
Bernardes de Jesus, B., Vera, E., Schnee-
berger, K., Tejera, A. M., Ayuso, E.,
Bosch, F., et al. (2012). Telomerase
gene therapy in adult and old mice
delays aging and increases longevity
without increasing cancer. EMBO
Mol. Med. 4, 691–704
Blackburn, E. H., and Gall, J. G. (1978).
A tandemly repeated sequence at
the termini of the extrachromosomal
ribosomal RNA genes in Tetrahy-
mena. J. Mol. Biol. 120, 33–53.
Bodnar, A. G., Ouellette, M., Frolkis,
M., Holt, S. E., Chiu, C. P., Morin,
G. B., et al. (1998). Extension of life-
span by introduction of telomerase
into normal human cells. Science 279,
349–352.
Bollmann, F. M. (2008). The many faces
of telomerase: emerging extratelom-
eric effects. Bioessays 30, 728–732.
Canela, A., Martin-Caballero, J., Flores,
J. M., and Blasco, M. A. (2004). Con-
stitutive expression of tert in thymo-
cytes leads to increased incidence and
dissemination of T-cell lymphoma in
Lck-Tert mice. Mol. Cell Biol. 24,
4275–4293.
Choi, J., Southworth, L. K., Sarin,
K. Y., Venteicher, A. S., Ma,
W., Chang, W., et al. (2008).
TERT promotes epithelial prolifera-
tion through transcriptional control
of a Myc- and Wnt-related develop-
mental program. PLoS Genet. 4, e10.
doi: 10.1371/journal.pgen.0040010
Cohen, S. B., Graham, M. E., Lovrecz,
G. O., Bache, N., Robinson, P. J.,
and Reddel, R. R. (2007). Protein
composition of catalytically active
human telomerase from immortal
cells. Science 315, 1850–1853.
Collins, K. (2006). The biogenesis
and regulation of telomerase holoen-
zymes. Nat. Rev. Mol. Cell Biol. 7,
484–494.
Cong,Y., and Shay, J. W. (2008). Actions
of human telomerase beyond telom-
eres. Cell Res. 18, 725–732.
Del Bufalo, D., Rizzo, A., Trisci-
uoglio, D., Cardinali, G., Torrisi, M.
R., Zangemeister-Wittke, U., et al.
(2005). Involvement of hTERT in
apoptosis induced by interference
with Bcl-2 expression and function.
Cell Death Differ. 12, 1429–1438.
Dokal, I. (2011). Dyskeratosis con-
genita. Hematology Am. Soc. Hema-
tol. Educ. Program 2011, 480–486.
Dudognon, C., Pendino, F., Hillion, J.,
Saumet, A., Lanotte, M., and Segal-
Bendirdjian, E. (2004). Death recep-
tor signaling regulatory function for
telomerase: hTERT abolishes TRAIL-
induced apoptosis, independently of
telomere maintenance. Oncogene 23,
7469–7474.
Flores, I., Cayuela, M. L., and Blasco, M.
A. (2005). Effects of telomerase and
telomere length on epidermal stem
cell behavior. Science 309, 1253–1256.
Flores, I., and Blasco, M. A. (2010).
The role of telomeres and telomerase
in stem cell aging. FEBS Lett. 584,
3826–3830.
Geserick, C., Tejera, A., Gonzalez-
Suarez, E., Klatt, P., and Blasco, M. A.
(2006). Expression of mTert in pri-
mary murine cells links the growth-
promoting effects of telomerase to
transforming growth factor-beta sig-
naling. Oncogene 25, 4310–4319.
Gonzalez-Suarez, E., Samper, E.,
Ramirez, A., Flores, J. M., Martin-
Caballero, J., Jorcano, J. L., et al.
(2001). Increased epidermal tumors
and increased skin wound healing
in transgenic mice overexpressing
the catalytic subunit of telom-
erase, mTERT, in basal keratinocytes.
EMBO J. 20, 2619–2630.
Gordon, D. M., and Santos, J. H. (2010).
The emerging role of telomerase
reverse transcriptase in mitochon-
drial DNA metabolism. J. Nucleic
Acids 2010, 390791.
Greider, C. W., and Blackburn, E. H.
(1985). Identiﬁcation of a speciﬁc
telomere terminal transferase activ-
ity in Tetrahymena extracts. Cell 43,
405–413.
Gu, B. W., Bessler, M., and Mason,
P. J. (2008). A pathogenic dyskerin
mutation impairs proliferation and
activates a DNA damage response
independent of telomere length in
mice. Proc. Natl. Acad. Sci. U.S.A.
105, 10173–10178.
Haendeler, J., Hoffmann, J., Rahman,
S., Zeiher, A. M., and Dimmeler,
S. (2003). Regulation of telomerase
activity and anti-apoptotic function
by protein–protein interaction and
phosphorylation. FEBS Lett. 536,
180–186.
Haendeler, J., Hoffmann, J., Zei-
her, A. M., and Dimmeler, S.
(2004). Antioxidant effects of statins
via S-nitrosylation and activation of
thioredoxin in endothelial cells: a
novel vasculoprotective function of
statins. Circulation 110, 856–861.
Haendeler, J., Drose, S., Buchner, N.,
Jakob, S., Altschmied, J., Goy, C.,
et al. (2009). Mitochondrial telom-
erase reverse transcriptase binds to
and protects mitochondrial DNA and
function from damage. Arterioscler.
Thromb. Vasc. Biol. 29, 929–935.
Harley, C. B. (2008). Telomerase and
cancer therapeutics. Nat. Rev. Cancer
8, 167–179.
Herschhorn, A., and Hizi, A. (2010).
Retroviral reverse transcriptases. Cell
Mol. Life Sci. 67, 2717–2747.
Hoffmeyer, K., Raggioli, A., Rudloff, S.,
Anton, R., Hierholzer, A., Del Valle,
I., et al. (2012).Wnt/beta-catenin sig-
naling regulates telomerase in stem
cells and cancer cells. Science 336,
1549–1554.
Indran, I. R., Hande, M. P., and Per-
vaiz, S. (2010). Tumor cell redox
state and mitochondria at the cen-
ter of the non-canonical activity of
telomerase reverse transcriptase. Mol.
Aspects Med. 31, 21–28.
Indran, I. R., Hande, M. P., and
Pervaiz, S. (2011). hTERT overex-
pression alleviates intracellular ROS
production, improves mitochondrial
function, and inhibits ROS-mediated
apoptosis in cancer cells. Cancer Res.
71, 266–276.
Kaguni, L. S. (2004). DNA polymerase
gamma, the mitochondrial replicase.
Annu. Rev. Biochem. 73, 293–320.
Kim, M., Xu, L., and Blackburn,
E. H. (2003). Catalytically active
human telomerase mutants with
allele-speciﬁc biological properties.
Exp. Cell Res. 288, 277–287.
Lee, J., Sung, Y. H., Cheong, C., Choi,
Y. S., Jeon, H. K., Sun, W., et al.
(2008). TERT promotes cellular and
organismal survival independently
of telomerase activity. Oncogene 27,
3754–3760.
Lindvall, C., Hou, M., Komurasaki, T.,
Zheng, C., Henriksson, M., Sedivy,
J. M., et al. (2003). Molecular char-
acterization of human telomerase
reverse transcriptase-immortalized
human ﬁbroblasts by gene expression
proﬁling: activation of the epiregulin
gene. Cancer Res. 63, 1743–1747.
Liu, P., and Demple, B. (2010). DNA
repair in mammalian mitochondria:
much more than we thought? Envi-
ron. Mol. Mutagen. 51, 417–426.
Lue, N. F., Bosoy, D., Moriarty, T. J.,
Autexier, C., Altman, B., and Leng,
S. (2005). Telomerase can act as a
www.frontiersin.org September 2012 | Volume 2 | Article 133 | 5
“fonc-02-00133” — 2012/9/27 — 13:43 — page 6 — #6
Chiodi and Mondello Telomerase beyond telomeres
template- and RNA-independent ter-
minal transferase. Proc. Natl. Acad.
Sci. U.S.A. 102, 9778–9783.
Maida, Y., Yasukawa, M., Furuuchi,
M., Lassmann, T., Possemato, R.,
Okamoto, N., et al. (2009). An RNA-
dependent RNA polymerase formed
by TERT and the RMRP RNA. Nature
461, 230–235.
Maida, Y., and Masutomi, K. (2011).
RNA-dependentRNApolymerases in
RNA silencing. Biol. Chem. 392,
299–304.
Majerska, J., Sykorova, E., and Fajkus,
J. (2011). Non-telomeric activities
of telomerase. Mol. Biosyst. 7,
1013–1023.
Martinez, P., and Blasco, M. A. (2011).
Telomeric and extra-telomeric roles
for telomerase and the telomere-
bindingproteins. Nat. Rev. Cancer 11,
161–176.
Masutomi, K., Yu, E. Y., Khurts, S., Ben-
Porath, I., Currier, J. L., Metz, G. B.,
et al. (2003). Telomerase maintains
telomere structure in normal human
cells. Cell 114, 241–253.
Masutomi, K., Possemato, R., Wong,
J. M., Currier, J. L., Tothova, Z.,
Manola, J. B., et al. (2005). The
telomerase reverse transcriptase reg-
ulates chromatin state and DNA
damage responses. Proc. Natl. Acad.
Sci. U.S.A. 102, 8222–8227.
Mondello, C., and Scovassi, A. I. (2004).
Telomeres, telomerase, and apopto-
sis. Biochem. Cell Biol. 82, 498–507.
Mondello, C., Bottone,M.G.,Noriki, S.,
Soldani, C., Pellicciari, C., and Sco-
vassi, A. I. (2006). Oxidative stress
response in telomerase-immortalized
ﬁbroblasts from a centenarian. Ann.
N. Y. Acad. Sci. 1091, 94–101.
Moyzis, R. K., Buckingham, J. M.,
Cram, L. S., Dani, M., Deaven, L. L.,
Jones, M. D., et al. (1988). A highly
conserved repetitive DNA sequence,
(TTAGGG)n, present at the telom-
eres of human chromosomes. Proc.
Natl. Acad. Sci. U.S.A. 85, 6622–6626.
Mukherjee, S., Firpo, E. J., Wang, Y.,
and Roberts, J. M. (2011). Separation
of telomerase functions by reverse
genetics. Proc. Natl. Acad. Sci. U.S.A.
108, E1363–E1371.
Okamoto, N., Yasukawa, M., Nguyen,
C., Kasim, V., Maida, Y., Pos-
semato, R., et al. (2011). Main-
tenance of tumor initiating cells
of deﬁned genetic composition by
nucleostemin. Proc. Natl. Acad. Sci.
U.S.A. 108, 20388–20393.
Palm, W., and de Lange, T. (2008). How
shelterin protects mammalian telom-
eres. Annu. Rev. Genet. 42, 301–334.
Park, J. I., Venteicher, A. S., Hong, J.
Y., Choi, J., Jun, S., Shkreli, M., et al.
(2009). Telomerase modulates Wnt
signalling by association with target
gene chromatin. Nature 460, 66–72.
Reya, T., and Clevers, H. (2005). Wnt
signalling in stem cells and cancer.
Nature 434, 843–850.
Ridanpaa, M., van Eenennaam, H.,
Pelin, K., Chadwick, R., Johnson, C.,
Yuan, B., et al. (2001). Mutations in
the RNA component of RNase MRP
cause a pleiotropic human disease,
cartilage-hair hypoplasia. Cell 104,
195–203.
Rodier, F., and Campisi, J. (2011). Four
faces of cellular senescence. J. Cell
Biol. 192, 547–556.
Sahin, E., Colla, S., Liesa, M.,
Moslehi, J., Muller, F. L., Guo, M.,
et al. (2011). Telomere dysfunction
inducesmetabolic andmitochondrial
compromise. Nature 470, 359–365.
Santos, J. H., Meyer, J. N., Sko-
rvaga, M., Annab, L. A., and
Van Houten, B. (2004). Mitochon-
drial hTERT exacerbates free-radical-
mediated mtDNA damage. Aging Cell
3, 399–411.
Santos, J. H., Meyer, J. N., and
Van Houten, B. (2006). Mitochon-
drial localization of telomerase as a
determinant for hydrogen peroxide-
induced mitochondrial DNA damage
and apoptosis. Hum. Mol. Genet. 15,
1757–1768.
Saretzki, G. (2009). Telomerase, mito-
chondria and oxidative stress. Exp.
Gerontol. 44, 485–492.
Sarin, K. Y., Cheung, P., Gilison,
D., Lee, E., Tennen, R. I., Wang,
E., et al. (2005). Conditional telom-
erase induction causes proliferation
of hair follicle stem cells. Nature 436,
1048–1052.
Sharma, G. G., Gupta, A., Wang, H.,
Scherthan, H., Dhar, S., Gandhi,
V., et al. (2003). hTERT associates
with human telomeres and enhances
genomic stability and DNA repair.
Oncogene 22, 131–146.
Sharma, N. K., Reyes, A., Green, P.,
Caron, M. J., Bonini, M. G., Gordon,
D. M., et al. (2012). Human telom-
erase acts as a hTR-independent
reverse transcriptase in mitochon-
dria. Nucleic Acids Res. 40, 712–725.
Shay, J. W., and Bacchetti, S. (1997).
A survey of telomerase activity in
human cancer. Eur. J. Cancer 33,
787–791.
Shkreli, M., Sarin, K. Y., Pech, M. F.,
Papeta, N., Chang, W., Brockman,
S. A., et al. (2012). Reversible cell-
cycle entry in adult kidney podocytes
through regulated control of telom-
erase and Wnt signaling. Nat. Med.
18, 111–119.
Smith, L. L., Coller, H. A., and
Roberts, J. M. (2003). Telomerase
modulates expression of growth-
controlling genes and enhances cell
proliferation. Nat. Cell Biol. 5,
474–479.
Stampfer, M. R., Garbe, J., Levine, G.,
Lichtsteiner, S., Vasserot, A. P., and
Yaswen, P. (2001). Expression of the
telomerase catalytic subunit, hTERT,
induces resistance to transforming
growth factor beta growth inhibition
in p16INK4A(−) human mammary
epithelial cells. Proc. Natl. Acad. Sci.
U.S.A. 98, 4498–4503.
Stewart, S. A., Hahn, W. C., O’Connor,
B. F., Banner, E. N., Lundberg, A. S.,
Modha, P., et al. (2002). Telomerase
contributes to tumorigenesis by a
telomere length-independent mech-
anism. Proc. Natl. Acad. Sci. U.S.A.
99, 12606–12611.
Storici, F., Bebenek, K., Kunkel, T. A.,
Gordenin, D. A., and Resnick, M. A.
(2007). RNA-templated DNA repair.
Nature 447, 338–341.
Strong, M. A., Vidal-Cardenas, S. L.,
Karim, B., Yu, H., Guo, N., and
Greider, C. W. (2011). Phenotypes
in mTERT+/− and mTERT−/− mice
are due to short telomeres, not
telomere-independent functions of
telomerase reverse transcriptase. Mol.
Cell Biol. 31, 2369–2379.
Tsai, R. Y., and McKay, R. D. (2002). A
nucleolar mechanism controlling cell
proliferation in stem cells and cancer
cells. Genes Dev. 16, 2991–3003.
Van Mater, D., Kolligs, F. T., Dlugosz, A.
A., and Fearon, E. R. (2003). Tran-
sient activation of beta-catenin sig-
naling in cutaneous keratinocytes is
sufﬁcient to trigger the active growth
phase of the hair cycle in mice. Genes
Dev. 17, 1219–1224.
van Steensel, B., Smogorzewska, A., and
De Lange, T. (1998). TRF2 protects
human telomeres from end-to-end
fusions. Cell 92, 401–413.
Vidal-Cardenas, S. L., and Greider, C.
W. (2010). Comparing effects of mTR
and mTERT deletion on gene expres-
sion and DNA damage response:
a critical examination of telom-
ere length maintenance-independent
roles of telomerase. Nucleic Acids Res.
38, 60–71.
Wege, H., Heim, D., Lütgehetmann,
M., Dierlamm, J., Lohse, A. W.,
and Brümmendorf, T. H. (2011).
Forced activation of β-catenin sig-
naling supports the transformation
of hTERT-immortalized human fetal
hepatocytes. Mol. Cancer Res. 9,
1222–1231.
Zhang, Y., Toh, L. L., Lau, P.,
and Wang, P. (2012). Telomerase
reverse transcriptase (TERT) is a
novel target of Wnt/β-catenin path-
way in human cancer. J. Biol. Chem.
doi: 10.1074/jbc.M112.368282 [Epub
ahead of print].
Zhu, J., Wang, H., Bishop, J.
M., and Blackburn, E. H. (1999).
Telomerase extends the lifespan
of virus-transformed human cells
without net telomere lengthening.
Proc. Natl. Acad. Sci. U.S.A. 96,
3723–3728.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 31 July 2012; accepted: 18
September 2012; published online: 28
September 2012.
Citation: Chiodi I and Mondello C
(2012) Telomere-independent functions
of telomerase in nuclei, cytoplasm, and
mitochondria. Front. Oncol. 2:133. doi:
10.3389/fonc.2012.00133
This article was submitted to Frontiers in
Cancer Molecular Targets and Therapeu-
tics, a specialty of Frontiers in Oncology.
Copyright © 2012 Chiodi and Mondello.
This is an open-access article distributed
under the terms of the Creative Commons
Attribution License, which permits use,
distribution and reproduction in other
forums, provided the original authors and
source are credited and subject to any
copyright notices concerning any third-
party graphics etc.
Frontiers in Oncology | Cancer Molecular Targets andTherapeutics September 2012 | Volume 2 | Article 133 | 6
